Rheumatology
Polymyalgia Rheumatica
BSR — diagnostic criteria, exclude mimics, low-dose prednisolone, slow taper, monitor for GCA.
Source: BSR 2010; EULAR/ACR 2015
Step 1 of ~3
info
Recognise
Age ≥50 (typically >65) + bilateral shoulder ± pelvic girdle pain + morning stiffness ≥45 min + ≥2 weeks duration + ESR/CRP ↑. Must exclude mimics: RA, polymyositis (CK normal in PMR), thyroid disease, depression, malignancy, infection, OA, fibromyalgia, statin myopathy. ALWAYS ask about GCA features (visual loss, headache, jaw claudication) — co-exists in 15%.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Dopamine (ICU — Vasopressor/Inotrope) · Catecholamine (Dose-Dependent Vasopressor/Inotrope)
- Hydroxocobalamin (High-Dose — Cyanide Antidote) · Cyanide Antidote (Vitamin B12 Precursor at High Dose)
- Dopamine hydrochloride · Inotrope / vasopressor (dose-dependent)
- Enalapril with hydrochlorothiazide · ACE inhibitor + thiazide diuretic (fixed-dose)
- Amiloride with Bumetanide · Potassium-Sparing Diuretic + Loop Diuretic (Fixed-Dose Combination)
- Amlodipine with Valsartan · Calcium-Channel Blocker + ARB (Fixed-Dose Combination Antihypertensive)
Pathways
- Cutaneous Lupus Erythematosus · BAD; EULAR
- Osteoporosis / Fragility Fracture · NOGG 2021; NICE NG147; NG224
- Arteritic AION (Giant Cell Arteritis) · RCOphth; BSR
- Osteoarthritis Hip / Knee Management · NICE NG226 (2022)
- Lupus Nephritis · EULAR/ERA-EDTA 2019; KDIGO 2024
- Rheumatoid Arthritis Management · NICE CG79 2018 / EULAR 2022
Decision support only. Always apply local guidelines and clinical judgement.